Boulevard starts up with $65M to pursue targeted autoimmune drugs

Part of story

Boulevard Bio launches with $65M to develop targeted autoimmune antibodies

Deerfield Management formed Boulevard Bio with renowned autoimmune researchers Georg Schett and Frank Nestle, raising $65 million to advance a trio of multifaceted antibodies for immune diseases.

Aug 12, 20263 sourcesVenture capital funding

Boulevard Bio launches with $65M to develop targeted autoimmune antibodies

Other sources for this story

MedCity News

Startup Boulevard Bio Launches With Immune Reset Pioneer Schett as Co-Founder - MedCity News

STAT News

Boulevard starts up with $65M to pursue targeted autoimmune drugs

Part of story

Boulevard Bio launches with $65M to develop targeted autoimmune antibodies

Other sources for this story

Startup Boulevard Bio Launches With Immune Reset Pioneer Schett as Co-Founder - MedCity News

Biotech company co-founded by top autoimmune researcher lays out plans with antibody therapies

Boulevard starts up with $65M to pursue targeted autoimmune drugs

Part of story

Boulevard Bio launches with $65M to develop targeted autoimmune antibodies

Other sources for this story

Startup Boulevard Bio Launches With Immune Reset Pioneer Schett as Co-Founder - MedCity News

Biotech company co-founded by top autoimmune researcher lays out plans with antibody therapies